Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals

Cytokine

Volumn 47, Issue 3, 2009, Pages 194-198

  Martin, Christina M ^a   Welge, Jeffrey A ^a   Shire, Norah J ^a   Shata, Mohamed T ^a   Sherman, Kenneth E ^a   Blackard, Jason T ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokine; HBV HIV co infection; Occult hepatitis B virus; Soluble Fas (sFas)

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; CYTOKINES; FEMALE; HEPATITIS B; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE;

HEPATITIS B VIRUS;

EID: 68949131082     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.06.005     Document Type: Article

References (40)

1. Chang J.J., and Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 85 (2006) 16-23
2. Isogawa M., Furuichi Y., and Chisari F.V. Oscillating CD8+ T cell effector functions after antigen recognition in the liver. Immunity 23 (2005) 53-63
3. Thio C.L., Seaberg E.C., Skolasky J.R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). The Lancet 360 (2002) 1921-1926
4. Szkaradkiewicz A., Jopek A., Wysocki J., Grzymislawski M., Malecka I., and Wozniak A. HBcAg-specific cytokine production by CD4 T lymphocytes of children with acute and chronic hepatitis B. Virus Res 97 (2003) 127-133
5. Jung M.C., and Pape G.R. Immunology of hepatitis B infection. Lancet Infect Dis 2 (2002) 43-50
6. Guidotti L.G., and Chisari F.V. Cytokine-mediated control of viral infections. Virology 273 (2000) 221-227
7. Blackburn S.D., and Wherry E.J. IL-10, T cell exhaustion and viral persistence. Trends Microbiol 15 (2007) 143-146
8. Norman J.E., Beebe G.W., Hoofnagle J.H., and Seeff L.B. Mortality follow-up of the 1942 epidemic of hepatitis B in the US Army. Hepatology 18 (1993) 790-797
9. Chichester J.A., Feitelson M.A., and Calkins C.E. Transient inhibition of Th1-type cytokine production by CD4+ T cells in hepatitis B core antigen immunized mice is mediated by regulatory T cells. Immunology 118 (2006) 438-448
10. Reignat S., Webster G.J.M., Brown D., Ogg G.S., King A., Seneviratne S.L., et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 195 (2002) 1089-1101
11. Beckebaum S., Cicinnati V.R., Zhang X., Ferencik S., Frilling A., Grosse-Wilde H., et al. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 109 (2003) 487-495
12. van der Molen R.G., Sprengers D., Binda R.S., de Jong E.C., Niesters H.G.M., Kusters J.G., et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40 (2004) 738-746
13. Boettler T., Panther E., Bengsch B., Nazarova N., Spangenberg H.C., Blum H.E., et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 80 (2006) 3532-3540
14. Sprengers D., van der Molen R.G., Kusters J.G., Hansen B., Niesters H.G.M., Schalm S.W., et al. Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B. J Med Virol 78 (2006) 561-568
15. Xu D., Fu J., Jin L., Zhang H., Zhou C., Zou Z., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177 (2006) 739-747
16. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J.W., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41 (2005) 771-778
17. Boettler T., Spangenberg H.C., Neumann-Haefelin C., Panther E., Urbani S., Ferrari C., et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79 (2005) 7860-7867
18. Hayashi N., and Mita E. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis. J Viral Hepat 6 (1999) 357-365
19. Iio S., Hayashi N., Mita E., Ueda K., Mochizuki K., Hiramatsu N., et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29 (1998) 517-523
20. Jodo S., Kobayashi S., Nakajima Y., Matsunaga T., Nakayama N., Ogura N., et al. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 112 (1998) 166-171
21. Khabar K.S.A., Al-Zoghaibi F., Al-Ahdal M.N., Murayama T., Dhalla M., Mukaida N., et al. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med 186 (1997) 1077-1085
22. Friedman S.L. Liver fibrosis-from bench to bedside. J Hepatol 38 (2003) 38-53
23. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
24. Matsuzaki K., Date M., Furukawa F., Tahashi Y., Matsushita M., Sakitani K., et al. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res 60 (2000) 1394-1402
25. Shire N.J., Rouster S.D., Stanford S.D., Blackard J.T., Martin C.M., Fichtenbaum C.J., et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. JAIDS 44 (2007) 309-314
26. Hu K.-Q. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9 (2002) 243-257
27. Lyon D.E., McCain N.L., Walter J., and Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57 (2008) 51-58
28. Hoge E.A., Brandstetter K., Moshier S., Pollack M.H., Wong K.K., and Simon N.M. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety 26 (2009) 447-455
29. Shimada A., Morimoto J., Kodama K., Suzuki R., Oikawa Y., Funae O., et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 24 (2001) 510-515
30. Wetzig T., Petri J.B., Mittag M., and Haustein U.F. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 290 (1998) 187-190
31. Hefler L., Mayerhofer K., Nardi A., Reinthaller A., Kainz C., and Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 96 (2000) 65-69
32. Suzuki K., Endo R., Nakamura N., Yatomi T., Iwai M., Abe K., et al. Serum levels of soluble Fas ligand in patients with acute and fulminant hepatitis: relationship with soluble Fas, tumor necrosis factor [alpha] and TNF receptor-1. Hepatol Res 17 (2000) 19-30
33. Scala E., Pallotta S., Frezzolini A., Abeni D., Barbieri C., Sampogna F., et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138 (2004) 540-546
34. Ayada M., Ishikawa T., Okumura A., Tanabe J., Ito H., Ohashi T., et al. Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatol Res 34 (2006) 214-221
35. Breen E.C. Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther 95 (2002) 295-304
36. Song L.H., Binh V.Q., Duy D.N., Kun J.F.J., Bock T.C., Kremsner P.G., et al. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. J Clin Virol 28 (2003) 93-103
37. Wang J., Zhao J.-H., Wang P.-P., and Xiang G.-J. Expression of CXC chemokine IP-10 in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 7 (2008) 45-50
38. Izmailova E., Bertley F.M.N., Huang Q., Makori N., Miller C.J., Young R.A., et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 9 (2003) 191-197
39. Wetzel M.A., Steele A.D., Henderson E.E., and Rogers T.J. The effect of X4 and R5 HIV-1 on C, C-C, and C-X-C chemokines during the early stages of infection in human PBMCs. Virology 292 (2002) 6-15
40. Lapinski T.W., Kowalczuk O., Prokopowicz D., and Chyczewski L. Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients. World J Gastroenterol 10 (2004) 3650-3653